规格或纯度 | ≥98% |
---|---|
英文名称 | Bardoxolone |
别名 | CDDO;RTA 401 |
英文别名 | CDDO;RTA 401;RTA401;RTA-401;2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid |
生化机理 |
Bardoxolone methyl, previously known as RTA 402, is the lead molecule in Reata's portfolio of Antioxidant Inflammation Modulators (AIMs). The AIMs are potent inducers of the transcription factor Nrf2, an important biological target that controls the production of many of the body's antioxidant and detoxification enzymes. Because oxidative stress and inflammation occur throμghout the course of chronic kidney disease (CKD) and are known to contribute to loss of kidney function, agents that activate the Nrf2 pathway in patients with CKD may provide a novel method for preserving or improving kidney function. Bardoxolone methyl is currently being investigated as a potential oral once-a-day treatment for CKD. |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
备注 | 卖完停产,不再备货 |
产品介绍 |
Bardoxolone(RTA 402)是抗氧化炎症调节剂(AIM)的先导化合物,此类AIM是转录因子Nrf2诱导剂。 Bardoxolone(RTA 402) is the lead molecule in Reata's portfolio of Antioxidant Inflammation Modulators (AIMs). The AIMs are potent inducers of the transcription factor Nrf2. |
IUPAC Name | (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid |
---|---|
INCHI | InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1 |
InChi Key | TXGZJQLMVSIZEI-UQMAOPSPSA-N |
Canonical SMILES | CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)O)C |
PubChem CID | 400010 |
分子量 | 491.66 |
PubChem CID | 400010 |
---|---|
ChEMBL Ligand | CHEMBL1093059 |
CAS Registry No. | 218600-44-3 |
Wikipedia | Bardoxolone |
溶解性 | DMSO |
---|
Ligand ID | 2717 |
---|---|
名称 | bardoxolone |
别名 | CDDO |
类别 | Synthetic organic |
学名 | (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid |
生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
评价 |
Bardoxolone was a Phase 3 NF-κB signaling inhibitor |
1. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW et al.. (2005) Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress.. Proc Natl Acad Sci USA, 102 (12): (4584-9). [PMID:15767573] |
2. Rojas-Rivera J, Ortiz A, Egido J. (2012) Antioxidants in kidney diseases: the impact of bardoxolone methyl.. Int J Nephrol, 2012 (13): (321714). [PMID:22701794] |
3. Wu J, Liu X, Fan J, Chen W, Wang J, Zeng Y, Feng X, Yu X, Yang X. (2014) Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway.. Toxicology, 318 (13): (22-31). [PMID:24530882] |
4. Cleasby A, Yon J, Day PJ, Richardson C, Tickle IJ, Williams PA, Callahan JF, Carr R, Concha N, Kerns JK et al.. (2014) Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO.. PLoS ONE, 9 (6): (e98896). [PMID:24896564] |